Industry-sponsored trials not transparent enough: experts

EXPERTS have called on greater transparency in systematic reviews of drug-sponsored clinical trials to ensure the integrity of claims made about the efficacy of medications.

Writing in the British Medical Journal this month, Tom Jefferson, a researcher at the acute respiratory infections group for the Cochrane Collaboration, argues that researchers need to change the way information is identified, appraised and synthesised.

Industry-sponsored trials published in journals should be regarded as “marketing, unless proved otherwise”, he wrote.